$Elevai Labs (ELAB.US)$ NEWS Elevai Biosciences Highlights P...
NEWS
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
EL-22 demonstrated physiological, physical, and functional improvements in mdx mice, a model of Duchenne muscular dystrophy.
The preclinical data showed a significant increase in anti-myostatin IgG antibody concentration and a decrease in creatine kinase levels.
Administering EL-22 to mdx mice resulted in improved physical activity and motor function in rotarod tests.
Elevai plans to submit an IND application in 2025 for clinical trials combining EL-22 with GLP-1 receptor agonists, potentially revolutionizing obesity treatment.
The preclinical data showed a significant increase in anti-myostatin IgG antibody concentration and a decrease in creatine kinase levels.
Administering EL-22 to mdx mice resulted in improved physical activity and motor function in rotarod tests.
Elevai plans to submit an IND application in 2025 for clinical trials combining EL-22 with GLP-1 receptor agonists, potentially revolutionizing obesity treatment.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1030Followers
64Following
6966Visitors
Follow